Chemical Properties:
Package: Bottle, Aluminum foil bag, 25kg/Cardboard drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.Manufacturer with High Purity and Stable Quality Commercial Supply Favipiravir and Related Intermediates: Favipiravir CAS 259793-96-9 2-Aminopropanediamide CAS 62009-47-6 Diethyl Aminomalonate Hydrochloride CAS 13433-00-6 3,6-Dichloropyrazine-2-Carbonitrile CAS 356783-16-9 3,6-Difluoropyrazine-2-Carbonitrile CAS 356783-28-3 6-Fluoro-3-Hydroxypyrazine-2-Carbonitrile CAS 356783-31-8 6-Bromo-3-Hydroxypyrazine-2-Carboxamide CAS 259793-88-9 3-Hydroxypyrazine-2-Carboxamide CAS 55321-99-8| Item | Specifications |
| Appearance | White to Off-White Powder |
| Identification 1H-NMR | Consistent with proposed structure |
| Identification HPLC | Retention time of main peak in sample preparation should be correspond with the retention time of main peak in reference standard preparation |
| Identification Mass | Mass Spectrum is consistent with proposed structure |
| Melting Point | 188.0℃-193.0℃ |
| Related Substances (Area Normalization) | Any Single Impurity: ≤0.10% (HPLC) |
| Total Impurities: ≤1.0% (HPLC) | |
| Purity / Analysis Method | ≥99.0% (HPLC) |
| Moisture (K.F) | ≤0.50% |
| Residue on Ignition | ≤0.10% |
| Heavy Metals | ≤20ppm |
| Residue Solvents | |
| Methanol | ≤3000ppm |
| Isopropanol | ≤5000ppm |
| n-Heptane | ≤5000ppm |
| Ethanol | ≤5000ppm |
| Test Standard | Enterprise Standard |
| Usage | Active Pharmaceutical Ingredient (API); Treatment of COVID-19 |
Description:
Specifications:
Package & Storage:
| Chemical Name | Favipiravir |
| Synonyms | T-705; 6-Fluoro-3-Hydroxy-2-Pyrazinecarboxamide |
| CAS Number | 259793-96-9 |
| CAT Number | RF-API18 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C5H4FN3O2 |
| Molecular Weight | 157.1 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Favipiravir (T-705) (CAS 259793-96-9) is one of the 5 compounds recommended by WHO for the investigation of treatment of COVID-19. Favipiravir is a selective inhibitor of viral RNA-dependent RNA polymerase with activity against many RNA viruses, influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Favipiravir is a broad-spectrum antiviral drug that was cleared by the Drugs Controller General of India (DCGI) last week for “emergency restricted” use among Covid-19 patients. Favipiravir was originally developed in the late 1990s by a company that was later purchased by the Japanese firm Fujifilm as part of its transition from the photo business to healthcare. After being tested against a range of viruses, the drug was approved in Japan in 2014 for emergency use against flu epidemics or to treat new strains of influenza.
